Latest News and Press Releases

Tevogen evaluates acquisition of Sciometrix to build integrated clinical infrastructure and advance its 2026 revenue goals.

Tevogen evaluates acquisition of Sciometrix to build integrated clinical infrastructure and advance its 2026 revenue goals.

Tevogen said its Board will evaluate a potential one-time special cash dividend, contingent on future revenue and earnings milestones and Board approval.

Tevogen announced changes to its long-term stock-based incentive program, aligning awards with company milestones, including revenue.

WARREN, N.J., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that its Founder and CEO, Dr. Ryan Saadi has donated 230,000 of...

Tevogen honors Board Member Dr. Curtis Patton as Yale recognizes his distinguished career, underscoring the Company’s ongoing growth.

WARREN, N.J., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that it has been named to the 2025 New Jersey Power List by NJBIZ,...

Company intends to collaborate with government initiatives, Long COVID patient organizations, and major healthcare providers to expedite development of TVGN 489In recognition of the high volume of...

WARREN, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today expressed its gratitude to the U.S. Department of Health and Human Services...

Risk adjusted Net Present Value (rNPV) for TVGN 116 is estimated to exceed ~$325 million in the US alone. WARREN, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or...